Head and Neck Cancer Clinical Trial
Official title:
Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer
NCT number | NCT00824174 |
Other study ID # | 2008-0080 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | January 15, 2009 |
Last updated | October 1, 2012 |
Start date | December 2008 |
Verified date | October 2012 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Objectives:
The purpose of this study is to obtain descriptive information about the nature and extent
of body image concerns among surgical patients with head and neck cancer, satisfaction with
care received regarding body image issues, and interest in psychosocial services targeting
body image disturbance. Findings from this study provide important preliminary data to guide
future large scale research on the critical, yet understudied, psychosocial issue of body
image functioning for head and neck cancer patients. Information obtained from this study
can specifically be used to facilitate the development of appropriate disease-specific body
image instruments and to determine the need for body image focused psychosocial
interventions to enhance quality of life and the survivorship experience for these patients.
Primary Aims
1. To characterize the nature and extent of body image concerns in surgically treated
patients with head and neck cancer and determine preferences for psychosocial
intervention.
2. To compare body image and quality of life outcomes for patients at different time
points relative to initiation of treatment. Specific time points of interest are
pre-treatment, within one year of initial surgical treatment, and greater than 1 year
following initial surgical treatment.
Secondary Aim
1. To compare body image and quality of life outcomes for patients with oral cavity,
cutaneous, and midface cancers.
Status | Completed |
Enrollment | 289 |
Est. completion date | |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. 18 years of age or older 2. Able to provide written informed consent to participate 3. Diagnosis of oral cavity, cutaneous or other midface cancer involving the head and neck region 4. Treatment plan includes surgical intervention 5. English speaking Exclusion Criteria: 1. Significant preexisting facial disfigurement from a previous trauma or congenital defect 2. Diagnosis of a serious mental illness involving formal thought disorder (e.g., schizophrenia) documented in medical record 3. Cognitive impairment (e.g., dementia, delirium) |
Observational Model: Cohort, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
United States | UT MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body image outcomes (i.e., Body Image Scale) for patients at different time points relative to initiation of treatment | Specific time points of interest are pre-treatment, within one year of initial surgical treatment, and greater than 1 year following initial surgical treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |